U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H30Cl2O6
Molecular Weight 521.429
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOMETASONE FUROATE

SMILES

[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]4(Cl)[C@@]2([H])CCC5=CC(=O)C=C[C@]45C

InChI

InChIKey=WOFMFGQZHJDGCX-ZULDAHANSA-N
InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1

HIDE SMILES / InChI
Molecular Formula C27H30Cl2O6
Molecular Weight 521.429
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019796s026lbl.pdf

Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. When glucocorticoids are discontinued, asthma stability may persist for several days or longer. Mometasone has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. Mometasone inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis. ELOCON Lotion (Mometasone) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Originator

Approval Year

1987
114
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2637
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8307
ELOCON

Approved Use

ELOCON Lotion is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients ≥12 years of age.

Launch Date

5.47171205E11
Preventing
Approved
8307
ASMANEX

Approved Use

ASMANEX TWISTHALER is a corticosteroid indicated for: • Maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older.

Launch Date

1.11205443E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
183 pg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26845343
320 μg 1 times / day steady-state, respiratory
dose: 320 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
MOMETASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.56 pg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/29669668
100 μg single, nasal
dose: 100 μg
route of administration: Nasal
experiment type: SINGLE
co-administered:
MOMETASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1560 pg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26845343
320 μg 1 times / day steady-state, respiratory
dose: 320 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
MOMETASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
92 pg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/29669668
100 μg single, nasal
dose: 100 μg
route of administration: Nasal
experiment type: SINGLE
co-administered:
MOMETASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
19.24 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/29669668
100 μg single, nasal
dose: 100 μg
route of administration: Nasal
experiment type: SINGLE
co-administered:
MOMETASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1.5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020762s053lbl.pdf
MOMETASONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
unhealthy, 0.5 - 2 yeas
n = 63
Health Status: unhealthy
Condition: dermatoses
Age Group: 0.5 - 2 yeas
Sex: unknown
Population Size: 63
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
Other AEs: Glucocorticoid decreased, Skin and subcutaneous conditions NEC...
Other AEs:
Glucocorticoid decreased (1 patient)
Skin and subcutaneous conditions NEC (1 patient)
Skin bacterial infection (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
unhealthy, adult
n = 812
Health Status: unhealthy
Condition: dermatoses
Age Group: adult
Sex: unknown
Population Size: 812
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
Other AEs: Pruritus, Skin atrophy...
Other AEs:
Pruritus (4.8%)
Skin atrophy (4.8%)
Tingling (4.8%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Glucocorticoid decreased 1 patient
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
unhealthy, 0.5 - 2 yeas
n = 63
Health Status: unhealthy
Condition: dermatoses
Age Group: 0.5 - 2 yeas
Sex: unknown
Population Size: 63
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
Skin and subcutaneous conditions NEC 1 patient
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
unhealthy, 0.5 - 2 yeas
n = 63
Health Status: unhealthy
Condition: dermatoses
Age Group: 0.5 - 2 yeas
Sex: unknown
Population Size: 63
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
Skin bacterial infection 1 patient
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
unhealthy, 0.5 - 2 yeas
n = 63
Health Status: unhealthy
Condition: dermatoses
Age Group: 0.5 - 2 yeas
Sex: unknown
Population Size: 63
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
Pruritus 4.8%
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
unhealthy, adult
n = 812
Health Status: unhealthy
Condition: dermatoses
Age Group: adult
Sex: unknown
Population Size: 812
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
Skin atrophy 4.8%
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
unhealthy, adult
n = 812
Health Status: unhealthy
Condition: dermatoses
Age Group: adult
Sex: unknown
Population Size: 812
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
Tingling 4.8%
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
unhealthy, adult
n = 812
Health Status: unhealthy
Condition: dermatoses
Age Group: adult
Sex: unknown
Population Size: 812
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1670

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C8
869
BCRP
545

P-gp
1491
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C8
923
 yes [IC50 0.327 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
BCRP
545
 likely
P-gp
1491
 likely
CYP3A4
1670
 yes
unlikely (co-administration study)
Comment: ketoconazole 200 mg (as well as placebo) were given twice daily concomitantly on Days 4 to 9. Mometasone furoate plasma concentrations were <150 pcg/mL on Day 3 prior to coadministration of ketoconazole or placebo. Following concomitant administration of ketoconazole, 4 out of 12 subjects in the ketoconazole treatment group (n=12) had peak plasma concentrations of mometasone furoate >200 pcg/mL on Day 9 (211-324 pcg/mL)
Page: 22,23
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:6970
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6970
ZINC
ZINC000004097440
http://zinc15.docking.org/substances/ZINC000004097440
PubMed

PubMed

TitleDatePubMed
Efficacy and safety of ketotifen eye drops as adjunctive therapy to mometasone nasal spray in subjects with seasonal allergic rhinoconjunctivitis.
2003
Cough and its importance in COPD.
2006
The benefits of combined treatment with corticosteroids and long-acting beta agonists.
2006
Pharmacological treatment of chronic obstructive pulmonary disease.
2006
Alternative therapies in antibiotic-resistant infection.
2006
Antimicrobial silk clothing in the treatment of atopic dermatitis proves comparable to topical corticosteroid treatment.
2006
Mometasone and beclomethasone comparison article observations.
2006 May
Novel insights into the aetiology and pathophysiology of increased airway inflammation during COPD exacerbations.
2006 May 22
Future therapeutic treatment of COPD: struggle between oxidants and cytokines.
2007
Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations.
2007
Evidence-based selection of inhaled corticosteroid for treatment of chronic asthma.
2007 Jan-Feb
Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.
2007 Jul
Seborrhoeic dermatitis.
2007 Jul 1
Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber.
2007 Jul-Aug
Montelukast in the management of allergic rhinitis.
2007 Jun
The role of mometasone furoate aqueous nasal spray in the treatment of adenoidal hypertrophy in the pediatric age group: preliminary results of a prospective, randomized study.
2007 Jun
Synergistic effect of formoterol and mometasone in a mouse model of allergic lung inflammation.
2007 Sep
[Patient preference survey on the lack of taste and odor of Nasonex nasal spray. Which impact on compliance to treatment?].
2008
Airways inflammation and treatment during acute exacerbations of COPD.
2008
Vancomycin-induced DRESS syndrome in a female patient.
2008
New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide.
2008 Apr
New approaches to managing asthma: a US perspective.
2008 Apr
Effect of allergic rhinitis on the use and cost of health services by children with asthma.
2008 Aug 30
Mometasone furoate in the management of asthma: a review.
2008 Dec
Foxp3+ T regulatory cells (Tregs) are increased in nasal polyps (NP) after treatment with intranasal steroid.
2008 Dec
A prospective clinical review of "multi model" approach for treating ear keloids.
2008 Jan
Relative oral corticosteroid-sparing effect of 7 inhaled corticosteroids in chronic asthma: a meta-analysis.
2008 Jul
Chronic hypokalemia due to excessive cola consumption: a case report.
2008 Jul 14
Expression of chloride channel protein CLC-3 in patients with allergic rhinitis: effect of topical corticosteroid treatment.
2008 Mar
[The effect of desloratadine on quality of life of patients with seasonal allergic rhinitis].
2008 May
Antibacterial activity of mometasone furoate.
2008 May
One-year treatment with mometasone furoate in chronic obstructive pulmonary disease.
2008 Nov 13
Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis.
2008 Oct
Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study.
2008 Sep 2
Local cytokines and clinical symptoms in children with allergic rhinitis after different treatments.
2009
Comparison of corticosteroid nasal sprays in relation to concomitant use and cost of other prescription medications to treat allergic rhinitis symptoms: retrospective cohort analysis of pharmacy claims data.
2009
Bronchial diffusing capacity of nitric oxide is increased in patients with allergic rhinitis.
2009
A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care.
2009 Aug
Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children.
2009 Aug
Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial.
2009 Dec 16
Using nasal steroids to treat nasal obstruction caused by adenoid hypertrophy: does it work?
2009 Feb
Inhaled corticosteroids for asthma: are they all the same?
2009 Feb
Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control.
2009 Jan 2
Use of mometasone furoate to prevent polyp relapse after endoscopic sinus surgery.
2009 Mar
Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale.
2009 May 27
Effect of the inhaled corticosteroid mometasone on small airway patency in patients with asthma.
2009 May-Jun
Treatment of postviral olfactory loss with glucocorticoids, Ginkgo biloba, and mometasone nasal spray.
2009 Oct
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Alitretinoin--its use in intractable hand eczema and other potential indications.
2009 Sep 21
Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire.
2010 Feb
Patents

Patents

JP4589928B2
9

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Can also be used as inhalation powder http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021067s013lbl.pdf
Apply a few drops to the affected skin areas once daily and massage lightly until it disappears.
Route of Administration: Topical
In Vitro Use Guide
Mac-1 expression and human eosinophil migration were effectively downregulated by preincubation with Mometasone at 1, 10 and 100 nM
Substance Class Chemical
Created
by admin
on Fri Dec 16 16:45:58 UTC 2022
Edited
by admin
on Fri Dec 16 16:45:58 UTC 2022
Record UNII
04201GDN4R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOMETASONE FUROATE
EP   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
MOMETASONE FUROATE [EP MONOGRAPH]
Common Name English
(11.BETA.,16.ALPHA.)-9,21-DICHLORO-17-((2-FURANYLCARBONYL)OXY)-11-HYDROXY-16-METHYLPREGNA-1,4-DIENE-3,20-DIONE
Common Name English
SINUVA
Brand Name English
LYR-210
Code English
9,21-Dichloro-11?,17-dihydroxy-16?-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)
Common Name English
MOMETASONE FUROATE [USP MONOGRAPH]
Common Name English
MOMETASONE FUROATE [ORANGE BOOK]
Common Name English
SCH 32088
Code English
MOMETASONE FUROATE COMPONENT OF DULERA
Common Name English
Mometasone furoate [WHO-DD]
Common Name English
SCH-32088
Code English
LYR-220 ACTIVE COMPONENT MOMETASONE FUROATE
Code English
MOMETASONE FUROATE [USAN]
Common Name English
MOMETASONE FUROATE [USP-RS]
Common Name English
ASMANEX
Brand Name English
MOMETASONE FUROATE [JAN]
Common Name English
DULERA COMPONENT MOMETASONE FUROATE
Common Name English
MOMETASONE FUROATE [GREEN BOOK]
Common Name English
MOMETASONE FUROATE ANHYDROUS
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 9,21-DICHLORO-17-((2-FURANYLCARBONYL)OXY)-11-HYDROXY-16-METHYL-, (11.BETA.,16.ALPHA.)
Common Name English
ELOCON
Brand Name English
NSC-760077
Code English
LYR210
Code English
MOMETASONE FUROATE [VANDF]
Common Name English
MOMETASONE FUROATE [MART.]
Common Name English
NSC-746171
Code English
MOMETASONE FUROATE [MI]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 691019
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
NCI_THESAURUS C29505
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
Code System Code Type Description
NSC
746171
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
FDA UNII
04201GDN4R
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
EVMPD
SUB166214
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
EPA CompTox
DTXSID4023333
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
CAS
83919-23-7
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
EVMPD
SUB03318MIG
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
ChEMBL
CHEMBL1161
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
WIKIPEDIA
MOMETASONE FUROATE
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
USAN
X-51
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
MERCK INDEX
M7597
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY Merck Index
RXCUI
30145
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY RxNorm
CHEBI
47564
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
DAILYMED
04201GDN4R
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
PUBCHEM
441336
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
NCI_THESAURUS
C29268
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
NSC
760077
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
DRUG CENTRAL
1832
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
DRUG BANK
DB14512
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
RS_ITEM_NUM
1445470
Created by admin on Fri Dec 16 16:45:58 UTC 2022 , Edited by admin on Fri Dec 16 16:45:58 UTC 2022
PRIMARY
Related Record Type Details
Structure of MOMETASONE FUROATE MONOHYDRATE
SALT/SOLVATE -> PARENT
Structure of MOMETASONE FUROATE MONOHYDRATE
SOLVATE->ANHYDROUS
Related Record Type Details
Structure of ICOMETHASONE 21-MESYLATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 9-DECHLORO-11-OXO MOMETASONE FUROATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of MOMETASONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 21-HYDROXY DESCHLOROMOMETASONE FUROATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 9,21-DICHLORO-17-((2-FURANYLCARBONYL)OXY)-11-HYDROXY-16-METHYLPREGNA-1,4-DIENE-3,20-DIONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6-OXO MOMETASONE FUROATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 21-CHLORO-9,11.BETA.-EPOXY-17-HYDROXY-16.ALPHA.-METHYL-9.BETA.-PREGNA-1,4-DIENE-3,20-DIONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ICOMETASONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 9,11-EPOXIDEMOMETASONE FUROATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of MOMETASONE-11,17-DIFUROATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 9-CHLORO-11.BETA.-HYDROXY-21-((METHANESULFONYL)OXY)-16.ALPHA.-METHYL-3,20-DIOXOPREGNA-1,4-DIEN-17-YL FURAN-2-CARBOXYLATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 21-CHLORO-16.ALPHA.-METHYL-3,20-DIOXOPREGNA-1,4,9(11)-TRIEN-17-YL FURAN-2-CARBOXYLATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 9-CHLORO-11.BETA.,17-DIHYDROXY-16.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of DEXAMETHASONE 9,11-EPOXIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of (11.BETA.,16.ALPHA.,17.ALPHA.)-9-CHLORO-17-(2,2-DIOXIDO-5H-1,2-OXATHIOL-4-YL)-17-((2-FURANYLCARBONYL)OXY)-11-HYDROXY-16-METHYLANDROSTA-1,4-DIEN-3-ONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ICOMETASONE-21-ACETATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of MOMETASONE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966